Keyphrases
Sickle Cell Disease
100%
Red Cell Exchange
100%
Therapeutic Plasma Exchange
100%
Monoclonal Antibody
50%
LILRB1
50%
Multiple Organ Dysfunction
50%
Photoluminescent Nanoparticles
50%
Wash-free
50%
Colloidal Assembly
50%
Natural Killer Cells
50%
Adjunct Therapy
50%
Red Blood Cell Exchange
50%
Secondary Stroke Prevention
50%
Antitumor Effect
50%
Hemoglobin S
50%
Galectin-7
50%
Relative Reduction
50%
Treatment-resistant
50%
Systemic Loxoscelism
50%
Hemolytic Anemia
50%
CD4+ T Cells
50%
Programmed Death-ligand 1 (PD-L1)
50%
Brown Recluse Spider Bite
33%
Multiple Organ Dysfunction Syndrome
31%
Mn Nanoparticles
20%
Low Risk
16%
Exchange Programs
16%
Cerebrovascular Accident
16%
Glycosylation
16%
Skin Necrosis
16%
Severe Reactions
16%
Life-threatening
16%
Clinical Benefit
16%
Multiple Organ Failure
16%
Multiple Myeloma
14%
Disease Severity
12%
SOFA Score
12%
Length of Hospital Stay
12%
Immune Regulation
11%
SHP2
11%
Glycan-binding Proteins
11%
Healthy Donors
10%
Manganese-doped Zinc Sulfide
10%
Magnetic Substrate
10%
Magnetic Isolation
10%
Collective Properties
10%
Washing Step
10%
Cancer Patients
9%
Transient Ischemic Attack
8%
Medical Records
8%
Program Enrollment
8%
Blood Volume
8%
Stroke Risk
8%
Exchange Protocol
8%
American Society of Hematology
8%
Retrospective Chart Review
8%
Stroke Ischemic
8%
Stroke Prevention
8%
Stroke History
8%
Potential Gains
8%
ICU Admission
6%
Laboratory Markers
6%
Score Following
6%
Post-therapeutic
6%
Statistical Trends
6%
End-organ Disease
6%
Intensive Care Unit
6%
Admission Time
6%
End-organ Damage
6%
At Discharge
6%
No Significant Difference
6%
Leading Causes of Death
6%
Splenic Sequestration
6%
Acute Complications
6%
Damage Severity
6%
Acute Chest Syndrome
6%
Mortality Prediction
6%
Effective Treatment
6%
CD4+ T
5%
Overexpression
5%
CD4+ T Cell Depletion
5%
Patient Samples
5%
Dominant Negative
5%
Esophageal Cancer
5%
N-glycosylation
5%
Knock-in Mouse Model
5%
Surface Expression
5%
Small Interfering RNA (siRNA)
5%
Surface Stability
5%
Binding Assay
5%
Suppressive Activity
5%
Expression Stability
5%
Immunohistochemical Staining
5%
CD4 Cells
5%
In Vitro Culture
5%
Surface Interaction
5%
Mouse Tumor Model
5%
Medicine and Dentistry
Plasma Exchange
100%
Sickle-Cell Disease
75%
Patient with Sickle Cell Disease
62%
Apoplexy
56%
Adjuvant Therapy
50%
Hemolytic Anemia
50%
Spider Bite
50%
Multiple Organ Dysfunction Syndrome
47%
Erythrocyte
37%
Skin Necrosis
16%
Disease Severity
12%
SOFA Score
12%
Acute Chest Syndrome
6%
Medical Record
6%
Intensive Care Unit
6%
Hematology
6%
Erythrocyte
6%
Flexibility
6%
End Organ Damage
6%
Transient Ischemic Attack
6%
Study Subject
6%
Immunology and Microbiology
LILRB1
50%
Monoclonal Antibody
50%
Natural Killer Cell
50%
Multiple Myeloma
14%